KR102092509B1 - Food composition for preventing and improving of dementia - Google Patents
Food composition for preventing and improving of dementia Download PDFInfo
- Publication number
- KR102092509B1 KR102092509B1 KR1020190108040A KR20190108040A KR102092509B1 KR 102092509 B1 KR102092509 B1 KR 102092509B1 KR 1020190108040 A KR1020190108040 A KR 1020190108040A KR 20190108040 A KR20190108040 A KR 20190108040A KR 102092509 B1 KR102092509 B1 KR 102092509B1
- Authority
- KR
- South Korea
- Prior art keywords
- root
- hot water
- fruit
- kinds
- white
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 22
- 206010012289 Dementia Diseases 0.000 title claims description 22
- 235000013305 food Nutrition 0.000 title claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 74
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 68
- 239000000284 extract Substances 0.000 claims abstract description 61
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 claims abstract description 35
- 241000209140 Triticum Species 0.000 claims abstract description 32
- 235000021307 Triticum Nutrition 0.000 claims abstract description 32
- 239000012141 concentrate Substances 0.000 claims abstract description 8
- 235000002789 Panax ginseng Nutrition 0.000 claims description 35
- 229940107131 ginseng root Drugs 0.000 claims description 30
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 235000008504 concentrate Nutrition 0.000 claims description 7
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 5
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 241000759833 Cornus officinalis Species 0.000 claims description 4
- 235000008216 herbs Nutrition 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 230000002829 reductive effect Effects 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 239000001506 calcium phosphate Substances 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 239000008213 purified water Substances 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 240000007472 Leucaena leucocephala Species 0.000 claims description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- 229940072056 alginate Drugs 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 2
- 239000001527 calcium lactate Substances 0.000 claims description 2
- 235000011086 calcium lactate Nutrition 0.000 claims description 2
- 229960002401 calcium lactate Drugs 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- 239000000378 calcium silicate Substances 0.000 claims description 2
- 229910052918 calcium silicate Inorganic materials 0.000 claims description 2
- 235000012241 calcium silicate Nutrition 0.000 claims description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 235000010980 cellulose Nutrition 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- 239000008121 dextrose Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 2
- 239000002480 mineral oil Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 2
- 229960003415 propylparaben Drugs 0.000 claims description 2
- 239000010865 sewage Substances 0.000 claims description 2
- 235000020374 simple syrup Nutrition 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 235000010356 sorbitol Nutrition 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000000454 talc Substances 0.000 claims description 2
- 229910052623 talc Inorganic materials 0.000 claims description 2
- 235000012222 talc Nutrition 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims 2
- 230000000996 additive effect Effects 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 1
- 235000015459 Lycium barbarum Nutrition 0.000 abstract description 34
- 241000209020 Cornus Species 0.000 abstract description 28
- 235000012907 honey Nutrition 0.000 abstract description 28
- 239000003814 drug Substances 0.000 abstract description 23
- 230000000694 effects Effects 0.000 abstract description 23
- 240000006394 Sorghum bicolor Species 0.000 abstract description 22
- 235000011684 Sorghum saccharatum Nutrition 0.000 abstract description 22
- 229940079593 drug Drugs 0.000 abstract description 15
- 241000196324 Embryophyta Species 0.000 abstract description 14
- 239000009122 Saeng-Ji-Hwang Substances 0.000 abstract description 9
- 239000004615 ingredient Substances 0.000 abstract description 6
- 235000021028 berry Nutrition 0.000 abstract description 4
- 235000015872 dietary supplement Nutrition 0.000 abstract description 3
- 235000013376 functional food Nutrition 0.000 abstract description 3
- 244000241838 Lycium barbarum Species 0.000 abstract 1
- 244000241872 Lycium chinense Species 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 15
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 14
- 230000036039 immunity Effects 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 208000024827 Alzheimer disease Diseases 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000011818 5xFAD mouse Methods 0.000 description 7
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 7
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 7
- 108010041191 Sirtuin 1 Proteins 0.000 description 7
- 210000002540 macrophage Anatomy 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 239000002504 physiological saline solution Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 240000004371 Panax ginseng Species 0.000 description 5
- 102000000344 Sirtuin 1 Human genes 0.000 description 5
- 240000001417 Vigna umbellata Species 0.000 description 5
- 235000011453 Vigna umbellata Nutrition 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 235000008434 ginseng Nutrition 0.000 description 5
- 230000005965 immune activity Effects 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 235000015468 Lycium chinense Nutrition 0.000 description 4
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 4
- 235000003140 Panax quinquefolius Nutrition 0.000 description 4
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 4
- 235000011613 Pinus brutia Nutrition 0.000 description 4
- 241000018646 Pinus brutia Species 0.000 description 4
- 230000002292 Radical scavenging effect Effects 0.000 description 4
- HLXRWTJXGMHOFN-XJSNKYLASA-N Verbenalin Chemical compound O([C@@H]1OC=C([C@H]2C(=O)C[C@H](C)[C@H]21)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HLXRWTJXGMHOFN-XJSNKYLASA-N 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 3
- 208000037259 Amyloid Plaque Diseases 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000012676 herbal extract Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 3
- 230000003071 parasitic effect Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 235000019155 vitamin A Nutrition 0.000 description 3
- 239000011719 vitamin A Substances 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 229940045997 vitamin a Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 2
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 2
- YTZSBJLNMIQROD-SFBCHFHNSA-N Morroniside Chemical compound O([C@@H]1OC=C([C@H]2C[C@H](O)O[C@@H](C)[C@H]21)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YTZSBJLNMIQROD-SFBCHFHNSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 241000405911 Rehmannia glutinosa Species 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 201000004810 Vascular dementia Diseases 0.000 description 2
- HLXRWTJXGMHOFN-UHFFFAOYSA-N Verbenalin Natural products C12C(C)CC(=O)C2C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O HLXRWTJXGMHOFN-UHFFFAOYSA-N 0.000 description 2
- 229930003451 Vitamin B1 Natural products 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000003925 brain function Effects 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 2
- 235000011869 dried fruits Nutrition 0.000 description 2
- 230000002964 excitative effect Effects 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 229960002715 nicotine Drugs 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- YTZSBJLNMIQROD-UHFFFAOYSA-N (4aS)-1c-beta-D-glucopyranosyloxy-6xi-hydroxy-8t-methyl-(4ar,8ac)-5,6,8,8a-tetrahydro-1H,4aH-pyrano[3,4-c]pyran-4-carboxylic acid methyl ester Natural products C12C(C)OC(O)CC2C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O YTZSBJLNMIQROD-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 240000005020 Acaciella glauca Species 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 1
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 1
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000256846 Apis cerana Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 235000014036 Castanea Nutrition 0.000 description 1
- 241001070941 Castanea Species 0.000 description 1
- QIIDATRCGITYRZ-UHFFFAOYSA-N Catalpol Natural products OCC1OC(OC2OC=CC3C(O)C(=C(CO)C23)O)C(O)C(O)C1O QIIDATRCGITYRZ-UHFFFAOYSA-N 0.000 description 1
- 240000004385 Centaurea cyanus Species 0.000 description 1
- 235000005940 Centaurea cyanus Nutrition 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- 206010009866 Cold sweat Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 241000331432 Cynanchum wilfordii Species 0.000 description 1
- 235000018782 Dacrydium cupressinum Nutrition 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 239000009429 Ginkgo biloba extract Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- AMBQHHVBBHTQBF-UHFFFAOYSA-N Loganin Natural products C12C(C)C(O)CC2C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O AMBQHHVBBHTQBF-UHFFFAOYSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- SKPPEIDJGJGRGK-UHFFFAOYSA-N Panacen Natural products CCC1=CC=CC2=C1C1OC(C=C=CBr)CC1O2 SKPPEIDJGJGRGK-UHFFFAOYSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 235000013697 Pinus resinosa Nutrition 0.000 description 1
- 241000013557 Plantaginaceae Species 0.000 description 1
- 241000201976 Polycarpon Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 208000021129 Postpartum disease Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 240000006079 Schisandra chinensis Species 0.000 description 1
- 235000008422 Schisandra chinensis Nutrition 0.000 description 1
- UFCGDBKFOKKVAC-DSASHONVSA-N Schisantherin A Chemical compound O([C@H]1C=2C=C(C(=C(OC)C=2C2=C(OC)C=3OCOC=3C=C2C[C@H](C)[C@@]1(O)C)OC)OC)C(=O)C1=CC=CC=C1 UFCGDBKFOKKVAC-DSASHONVSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- FLUADVWHMHPUCG-OVEXVZGPSA-N Verbascose Natural products O(C[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](OC[C@@H]2[C@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]3(CO)[C@H](O)[C@@H](O)[C@@H](CO)O3)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 FLUADVWHMHPUCG-OVEXVZGPSA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 241000736816 Xanthorhiza Species 0.000 description 1
- 240000008866 Ziziphus nummularia Species 0.000 description 1
- ILLGYRJAYAAAEW-QMMMGPOBSA-N abt-418 Chemical compound CN1CCC[C@H]1C1=CC(C)=NO1 ILLGYRJAYAAAEW-QMMMGPOBSA-N 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- LHAOFBCHXGZGOR-NAVBLJQLSA-N alpha-D-Manp-(1->3)-alpha-D-Manp-(1->2)-alpha-D-Manp Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1 LHAOFBCHXGZGOR-NAVBLJQLSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 230000006933 amyloid-beta aggregation Effects 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000002439 beta secretase inhibitor Substances 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000025698 brain inflammatory disease Diseases 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- LHDWRKICQLTVDL-PZYDOOQISA-N catalpol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2[C@@]3(CO)O[C@H]3[C@@H](O)[C@@H]2C=CO1 LHDWRKICQLTVDL-PZYDOOQISA-N 0.000 description 1
- UXSACQOOWZMGSE-UHFFFAOYSA-N catalposide Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(OC(=O)C=3C=CC(O)=CC=3)C2C=CO1 UXSACQOOWZMGSE-UHFFFAOYSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000002888 effect on disease Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019985 fermented beverage Nutrition 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 150000007946 flavonol Chemical class 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000003540 gamma secretase inhibitor Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- 229940068052 ginkgo biloba extract Drugs 0.000 description 1
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000005679 goldenseal Nutrition 0.000 description 1
- 229930186755 gomisin Natural products 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 229960004135 idebenone Drugs 0.000 description 1
- JGPMMRGNQUBGND-UHFFFAOYSA-N idebenone Chemical compound COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O JGPMMRGNQUBGND-UHFFFAOYSA-N 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- AMBQHHVBBHTQBF-UOUCRYGSSA-N loganin Chemical compound O([C@@H]1OC=C([C@H]2C[C@H](O)[C@H](C)[C@H]21)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O AMBQHHVBBHTQBF-UOUCRYGSSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- FYGDTMLNYKFZSV-UHFFFAOYSA-N mannotriose Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(O)C(O)C2O)CO)C(O)C1O FYGDTMLNYKFZSV-UHFFFAOYSA-N 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- LHDWRKICQLTVDL-UHFFFAOYSA-N methyl iridoid glycoside Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(O)C2C=CO1 LHDWRKICQLTVDL-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 201000003152 motion sickness Diseases 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 210000005037 parasympathetic nerve Anatomy 0.000 description 1
- 229940116257 pepper extract Drugs 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000010204 pine bark Nutrition 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001197 polyacetylene Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 108091006082 receptor inhibitors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- FLUADVWHMHPUCG-SWPIJASHSA-N verbascose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O4)O)O3)O)O2)O)O1 FLUADVWHMHPUCG-SWPIJASHSA-N 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/70—Clarifying or fining of non-alcoholic beverages; Removing unwanted matter
- A23L2/72—Clarifying or fining of non-alcoholic beverages; Removing unwanted matter by filtration
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
- A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/50—Polysaccharides, gums
- A23V2250/51—Polysaccharide
- A23V2250/5108—Cellulose
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/60—Sugars, e.g. mono-, di-, tri-, tetra-saccharides
- A23V2250/612—Lactose
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/60—Sugars, e.g. mono-, di-, tri-, tetra-saccharides
- A23V2250/628—Saccharose, sucrose
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/60—Sugars, e.g. mono-, di-, tri-, tetra-saccharides
- A23V2250/64—Sugar alcohols
- A23V2250/6418—Mannitol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/60—Sugars, e.g. mono-, di-, tri-, tetra-saccharides
- A23V2250/64—Sugar alcohols
- A23V2250/642—Sorbitol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
Abstract
본 발명은 생지황 뿌리생지황 뿌리, 백복령 뿌리, 백밀(꿀), 구기자 열매, 산수유 열매, 오미자 열매 및 백하수오 뿌리 등 8종 약재의 열수추출물에 관한 것으로 더욱 상세하게는 면역활성 증진 또는 치매 예방 및 개선에 효과가 있는 7종의 허브식물과 백밀의 열수추출물의 농축액을 유효성분으로 함유하는 건강보조 기능성 식품 조성물로 이용할 수 있는 뛰어난 효과가 있다.The present invention relates to hot water extracts of 8 kinds of medicines, such as saengjihwang root, saengjihwang root, Baekbokryeong root, white wheat (honey), goji berry, cornus berry, Omija fruit, and white sorghum root. There is an excellent effect that can be used as a health supplement functional food composition containing a concentrate of seven kinds of herbal plants and hot water extract of white wheat as an effective ingredient.
Description
본 발명은 생지황 뿌리, 홍삼근, 백복령 뿌리, 구기자 열매, 산수유 열매, 오미자 열매 및 백하수오 뿌리 등 7종의 허브식물과 백밀(꿀)의 열수추출물을 유효성분으로 함유하는 면역증강 또는 치매 예방 및 개선 기능성 식품 조성물에 관한 것으로, 더욱 상세하게는 상기 7종의 허브식물과 백밀의 열수추출물을 이용하여 알츠하이머와 같은 치매 예방 및 개선용 식품 조성물에 관한 것이다.The present invention prevents and improves immunity enhancement or dementia that contains 7 kinds of herbal plants, such as raw rhizome root, red ginseng root, Baekbokryeong root, goji berry fruit, cornus fruit, Omija fruit, and white sorghum root and hot water extract of white wheat (honey) as an active ingredient. The present invention relates to a functional food composition, and more particularly, to a food composition for preventing and improving dementia, such as Alzheimer's, using the seven kinds of herbal plants and hot water extract of white wheat.
최근 산업화와 환경의 변화 속에서 현대인들은 다양한 원인에 의한 면역력 저하로 인해 각종 질병에 노출되어 있으며, 이러한 질병 치료를 위해 막대한 비용을 소모하고 있다. 특히, 최근 오염된 공기 및 신생활 변화 등의 이유로 알러지성 질환은 여러 알러지 유발인자에 의해 인체 면역체계를 과도하게 항진시켜 대식세포와 같은 면역세포에서 TNF-α(tumor necrosis factor-α), IL-1(interleukin-1), IL-6(interleukin-6), 프로스타글란딘(prostagladin), 류코트리엔(luecotriene), MMP-9(matrix metalloproteinase-9) 및 산화질소(nitric oxide, NO)와 같은 염증유발 물질을 과도하게 유도하여 이는 염증반응으로 진행되어 여러가지 질병 및 면역 과민반응 증상 등을 일으키는 것으로 알려져 있다.In recent industrialization and changes in the environment, modern people are exposed to various diseases due to reduced immunity caused by various causes, and they are consuming enormous costs to treat these diseases. In particular, for allergic diseases due to recently polluted air and changes in new life, allergens excessively promote the human immune system by various allergens, causing TNF-α (tumor necrosis factor-α), IL in immune cells such as macrophages. Inflammatory substances such as -1 (interleukin-1), IL-6 (interleukin-6), prostaglandin, luecotriene, matrix metalloproteinase-9 (MMP-9) and nitric oxide (NO) It is known that by inducing excessively, it progresses to an inflammatory reaction and causes various diseases and immune hypersensitivity symptoms.
또, 이러한 면역체계의 붕괴로 인해 신경세포의 손상 및 손실로 뇌기능이 손상되면서 치매가 발병하고 있으며 그 치매의 발병시기도 점차 빨라지고 있다.In addition, dementia develops as brain function is impaired due to damage and loss of nerve cells due to the collapse of the immune system, and the onset time of dementia is gradually increasing.
이러한 치매(dementia)는 정상적으로 생활해오던 사람이 다양한 원인에 인해 뇌기능이 손상되면서 이전에 비해 인지 기능이 지속적이고 전반적으로 저하되는 일종의 증후군으로, 병리학적으로는 신경세포의 손상 및 손실에 의해 기억, 집중, 언어 및 인지 등에 심한 장애가 오랜 시간 동안 점진적으로 진행되어 궁극적으로는 사망에 이르게 하는 뇌 질환이다. 이러한 치매의 원인 질환들로는 알츠하이머병(Alzheimer's disease), 혈관성 치매(Vascular dementia), 파킨슨씨 병(Parkinson's disease), 루이체 치매(Lewy body dementia), 무도병(Huntington's disease), 크루츠펠트-야콥병(Creutzfeldt-Jacob disease), 픽스씨 병(Pick's disease) 등이 알려져 있다.Dementia is a kind of syndrome in which a person who has been living normally has brain function impaired due to various causes and the cognitive function is continuously and generally lower than before, and pathologically, memory is caused by damage and loss of nerve cells. It is a brain disease that causes severe disabilities such as concentration, language, and cognition and progresses gradually over a long period of time, ultimately leading to death. The causes of dementia include Alzheimer's disease, Vascular dementia, Parkinson's disease, Lewy body dementia, Huntington's disease, Creutzfeldt-Jakob disease Jacob disease, and Pick's disease are known.
그 중 알츠하이머 질환(AD)은 가장 흔한 퇴행성 뇌질환으로 점진적인 신경세포의 퇴화로 인해 인지능력 상실을 가져온다. 뇌 조직내 아밀로이드 플라그 및 아밀로이드로서 존재하는, 원섬유 형태의 아밀로이드-β 단백질 (Aβ)로 명명되는 39-43개 아미노산 펩티드의 축적을 특징으로 한다. 알츠하이머 병에서 Aβ 침착은 뇌의 신경세포 및 간질세포에게 유해하고, 그 결과 알츠하이머 병의 특징적인 특성인 뇌 염증 및 신경세포 사멸을 일으킨다. Alzheimer's disease (AD) is the most common degenerative brain disease and causes cognitive loss due to gradual degeneration of neurons. It is characterized by the accumulation of 39-43 amino acid peptides called amyloid-β protein (Aβ) in fibrillar form, present as amyloid plaques and amyloids in brain tissue. In Alzheimer's disease, Aβ deposition is detrimental to neurons and interstitial cells in the brain, resulting in brain inflammation and neuronal cell death, characteristic characteristics of Alzheimer's disease.
AD로 사망한 환자의 두뇌에서는 노인성 플라그(senile plaque)와 신경원섬유의 엉킴(neurofibrillary tangles)이 병리학적 특성으로 나타난다. 이 중 노인성 플라그는 세포 외부에 단백질과 죽은 세포 등이 축적되어 형성되는 것으로, 주 구성 성분은 아밀로이드-베타(Amyloid-β(Aβ)라는 펩티드이다.Senile plaque and neurofibrillary tangles in the brain of patients who die from AD appear as pathological features. Among them, senile plaque is formed by accumulation of proteins and dead cells outside the cell, and the main component is a peptide called amyloid-β (Aβ).
AD 환자의 주요 특징인 인지 작용의 점진적 상실은 비정상적으로 축적된 Aβ에 의해 유발되는 것으로 보인다. Aβ는 아밀로이드 전구 단백질(amyloid precursor protein: 이하 "APP"라 칭함)로부터 단백질 분해(proteolysis) 과정을 통해 생성된다. 전구물질인 APP는 β-세크라타제(BSCE) 및 γ-세크라타제에 의해 분해되어 Aβ가 생성된다. 그러나 α-세크라타제에 의해 APP가 절단될 경우 Aβ의 생성을 억제하고 신경세포 보호 효과를 나타내는 APPα의 생성을 유도하므로 α-세크라타제의 활성을 증가시키는 것이 알츠하이머병의 치료 또는 개선의 방법이다. 또한, 체내에서 SIRT1이 활성화되면 다양한 전사조절인자들을 탈아세틸화시킴으로써 α-세크라타제를 활성화시킨다.The gradual loss of cognitive function, a major characteristic of AD patients, appears to be caused by abnormally accumulated Aβ. Aβ is produced through a proteolysis process from amyloid precursor protein (hereinafter referred to as “APP”). The precursor APP is degraded by β-secretase (BSCE) and γ-secretase to produce Aβ. However, when the APP is cleaved by α-secretase, it inhibits the production of Aβ and induces the production of APPα, which has a neuroprotective effect. Therefore, increasing the activity of α-secretase increases treatment or improvement of Alzheimer's disease. to be. In addition, when SIRT1 is activated in the body, α-secretase is activated by deacetylation of various transcription regulators.
한편 니코틴 수용체 저해제인 ABT-418, 무스카린 수용체 저해제인 자노멜린, 아세틸콜린 전구체인 레시틴, 아세틸-L-카르니틴, 금속 킬레이터인 데스페리옥사민, 리오퀴놀, 베타-쉬트 브레이커인 iAβ5, iAβ11, 항산화제인 비타민 E, 은행잎 추출물, 멜라토닌, 이데베논, sAPP 방출제인 니코틴, 아세틸콜린, 카바콜, 베타 세크라타제 또는 감마 세크라타제 저해제인 OM99-1, OM99-2, OM99-3, Z-VLL-CHO, 항염증제인 NSAIDs계 약물 등이 개발되고 있으나, 아직 효과가 약간의 병리적 증상을 완화 또는 진행 정도를 늦추는 정도로 생겨 미미하거나 자체의 독성때문에 실제 적용이 어려운 물질이 대부분이어서 안정하며 효과적인 AD 치료제의 개발이 시급하다.Meanwhile, nicotine receptor inhibitors ABT-418, muscarinic receptor inhibitors xanomerlin, acetylcholine precursor lecithin, acetyl-L-carnitine, metal chelator desperioxamine, rioquinol, beta-sheet breaker iAβ5, iAβ11, Antioxidants vitamin E, ginkgo biloba extract, melatonin, idebenone, sAPP release agents nicotine, acetylcholine, carbacol, beta secretase or gamma secretase inhibitors OM99-1, OM99-2, OM99-3, Z-VLL -CHO, anti-inflammatory drugs such as NSAIDs are being developed, but the effect is still stable enough to mitigate some pathological symptoms or slow the progression. Development is urgent.
생지황(Rehmannia glutinosa)은 현삼과(Scrophulariaceae) 식물인 지황 (Rehmannia glutinosa Libosch.)의 근경으로, 주성분으로는 카탈폴(Catalpol), 베르바스코스 만니톨(Verbascose mannitol), 글루코스(Glucose), 마니노트리오스(Maninotriose), 비타민 A(Vitamin A)를 포함하고 있다. 생지황은 성분이 차고 맛이 달며 독이 없고 모든 열을 풀어주고 피를 깨뜨리며, 신음을 보하고 정(精)과 혈을 북돋아 주며, 혈증(血症)을 다스리는데 쓰인다.Rehmannia glutinosa is a rhizome of Rehmannia glutinosa Libosch., A plant of the Scrophulariaceae family, and its main components are Catalpol, Verbascose mannitol, Glucose, and Mannotriose. (Maninotriose), Vitamin A (Vitamin A). Saengjihwang is cold and tasteless, has no poison, releases all heat, breaks blood, moans, boosts blood and blood, and is used to control hememia.
홍삼(紅蔘)은 수삼(水蔘, Panax ginseng C.A. Meyer)의 뿌리를 쪄서 말린 붉은 인삼을 말한다. 홍삼의 주요 성분으로는 백삼과 같이 배당체(glycosides), 인삼향성분(panacen), 폴리아세틸렌계 화합물, 함질소성분, 플라보노이드, 비타민(B군), 미량원소, 효소, 항산화 물질과 유기산 및 아미노산 등이 있다. 홍삼은 중추신경에 대해서 진정작용과 흥분작용이 있으며, 순환계에 작용하여 고혈압이나 동맥경화의 예방효과가 있다고 알려져 있다. 그외에도 혈당치(血糖値)를 저하시켜 주고, 간을 보호하며, 내분비계에 작용하여 성행동(性行動)이나 생식효과에 간접적으로 유효하게 작용하며, 항염(抗炎) 및 항종양작용(抗腫瘍作用)이 있고, 방사선에 대한 방어효과와 피부를 보호하며 부드럽게 하는 작용이 있다. 또한 피로회복, 면역력 증진, 혈소판 응집 억제를 통한 혈액 흐름 개선에 관한 기능성이 인정되었다.Red ginseng (紅 蔘) refers to red ginseng dried from the roots of ginseng (水., Panax ginseng C.A. Meyer). The main components of red ginseng are glycosides, ginseng flavor components (panacen), polyacetylene compounds, nitrogen-containing components, flavonoids, vitamins (group B), trace elements, enzymes, antioxidants, organic acids and amino acids, like white ginseng. There is this. It is known that red ginseng has a sedative and excitatory effect on the central nervous system, and acts on the circulatory system to prevent hypertension or arteriosclerosis. In addition, it lowers blood sugar levels (血糖 値), protects the liver, acts on the endocrine system, indirectly acting on sexual and reproductive effects, and has anti-inflammatory and anti-tumor effects.腫 瘍 作用), has a protective effect against radiation and skin protection and softening effect. In addition, the functionality of improving blood flow through fatigue recovery, enhancing immunity, and inhibiting platelet aggregation was recognized.
백복령(Poria cocos Wolf)은 흰솔풍령이라고도 불리며 소나무 뿌리에 기생하는 버섯으로써, 비(脾)를 튼튼하게 하고 중초를 보해주며 습을 빼주고 수액대사를 돕고 정신을 안정시켜주는 효능이 있는 약재이다. 전국 각지의 소나무를 베어낸 곳에 자라며 재배도 한다. 베어 낸 지 여러 해 지난 소나무 뿌리에 기생하여 혹처럼 크게 자라는데, 소나무 그루터기 주변을 쇠꼬챙이로 찔러서 찾아낸다. 지름 30~50㎝ 쯤의 덩어리로 겉은 소나무 껍질처럼 거칠고 속은 희다. 적송의 뿌리에 기생하며 맛은 달고 심심하며 성질이 평(平)하여 보(補)하는 작용이 있고 이뇨작용을 하지만 강하지 않다. 옛날부터 강장제로 사용되었다. 폐경(肺經)·비경(脾經)·심경(心經)·신경(腎經)·방광경(膀胱經)에 작용하여 비장을 보하고 가래를 삭이며 정신을 안정시킨다. 약리실험 결과에 의하면 이뇨작용과 혈당량을 낮추는 작용, 진정작용 등을 하는 것으로 밝혀졌으며 면역 부활작용을 하는 것으로도 알려져 있다. 비장이 허(虛)하여 몸이 붓는 경우와 담음병에 사용한다. 또, 게우는 데나 복수·설사·건망증·수면장애 등에도 처방한다. 위·간·이자·신장 등의 질병에도 탁월한 효과가 있는 것으로 알려져 있으며, 질병을 앓고 난 후 허약한 사람이나 만성 위장병 환자 등의 치료를 위한 약재로 이용되고 남녀의 임독성 질병은 물론 모든 성병과 부인병에도 효과가 있는 것으로 알려져 있다. Baekboknyeong (Poria cocos Wolf) is a mushroom that is parasitic on the roots of pine trees, also known as white solpoongnyeong. It is a potent medicinal herb that strengthens rain, protects the middle and lowers moisture, helps with metabolism, and stabilizes the mind. It grows and grows in places where pine trees from all over the country are cut. It is parasitic on the roots of pine trees that have been cut for many years and grows large like a hump. It is found by stabbing around the stump of a pine tree. It is a lump about 30 ~ 50cm in diameter, rough on the outside like a pine bark, and white inside. It is parasitic on the root of red pine, tastes sweet, bored, and has a flattering effect, diuretic, but not strong. It has been used as a tonic since ancient times. It acts on the menopause, nasal passage, heart, nerve, and bladder mirror to protect the spleen, cut sputum and stabilize the mind. According to the results of pharmacological experiments, it was found that it has a diuretic effect, lowers blood sugar levels, and sedative effects. It is used for cases where the spleen is swelling and the body is swollen, and for damaging diseases. Also, Gew is prescribed for dena, revenge, diarrhea, forgetfulness, and sleep disorders. It is known to have an excellent effect on diseases such as stomach, liver, interest, and kidney, and is used as a medicine for the treatment of people with weakness or chronic gastrointestinal disease after suffering from the disease. It is known to be effective against gynecological diseases.
백밀(Apis cerana)은 기를 더해주고 중초(中焦)를 보해주고 폐를 자양하며 마른 것을 부드럽게 해주고 장을 부드럽게 하며 통증을 멎게하고 해독 살충하는 효능이 있는 꿀의 약재명이다. White wheat (Apis cerana) is a medicinal name for honey that has the effect of adding qi, nourishing the middle, nourishing the lungs, softening the dry, softening the intestines, relieving pain and detoxifying.
구기자(Lycium chinense)는 가지 과에 속하는 구기자나무의 열매이다. 구기자는 원형 또는 타원형의 장과이고 건조시켰을 때에 겉이 쭈글쭈글하고 속에는 많은 씨가 들어있다. 구기자의 성분은 Carotene 3.39㎎%, vitamin B1 0.23㎎%, vitamin B2 0.33㎎%, nicotin acid 1.7㎎%, vitamin C 3㎎%을 함유하고, β-sitosterol, linoleic acid 등 각종 무기성분 등을 다량 함유하고 있어 강장보신(强壯補身) 및 강압명목(强壓明目)의 효과를 지니고 있고, 저비중 콜레스테롤의 장내흡수를 억제 강하하여 간장보호에 효과적이며, 고혈압, 협심증, 동맥경화 및 당뇨병 등의 성인병에 탁월한 예방 및 치료 효과를 지니고 있는 동시에, 시력보호 효과도 뛰어난 것으로 알려져 있다.Wolfberry (Lycium chinense) is a fruit of the Wolfberry tree belonging to the branch family. Goji berries are round or elliptical berries, and when dried, they are crunchy and contain many seeds inside. The content of goji berry contains 3.39 mg% of Carotene, 0.23 mg% of vitamin B1, 0.33 mg% of vitamin B2, 1.7 mg% of nicotin acid, and 3 mg% of vitamin C, and contains a large amount of various inorganic ingredients such as β-sitosterol and linoleic acid. It is effective in protecting the liver by suppressing and lowering the intestinal absorption of low-specific cholesterol, and is effective in protecting the liver, such as hypertension, angina, arteriosclerosis and diabetes. It is known to have excellent prevention and treatment effects for adult diseases, and also excellent vision protection effects.
산수유(Cornus officinalis)는 층층나무과(山茶萸科:Cornaceae)에 속한 낙엽소교목인 산수유나무 (Cornus officinalis Sieb. et.Zucc)의 성숙한 열매를 건조한 것으로, 과육과 씨앗을 분리하여 육질은 술과 차 및 한약의 재료로 사용하며 과육(果肉)에는 코르닌(cornin), 모로니사이드(Morroniside), 로가닌(Loganin), 타닌(tannin), 사포닌(Saponin) 등의 배당체와 포도주산, 사과산, 주석산 등의 유기산이 함유되어 있고, 그밖에 비타민 A와 다량의 당(糖)도 포함되어 있다. 종자에는 팔미틴산, 올레인산, 리놀산 등이 함유되어 있다. 성분 중 코르닌은 부교감신경의 흥분작용이 있는 것으로 알려져 있다. 예로부터 한방에서는 과육을 약용하였다. "동의보감" "향약집성방" 등에 의하면 강음(强陰), 신정(腎精)과 신기(腎氣)보강, 수렴 등의 효능이 있다고 한다. 두통, 이명(耳鳴), 해수병, 해열, 월경과다 등에 약재로 쓰이며 식은땀, 야뇨증 등의 민간요법에도 사용된다. 차나 술로도 장복하며, 지한(止汗), 보음(補陰) 등의 효과가 있다. Cornus officinalis is a dried fruit of the cornus officinalis Sieb. Et.Zucc, a deciduous small tree belonging to the Cornus family. It is used as an ingredient in Chinese medicine, and in the flesh, glycosides such as cornin, morroniside, loganin, tannin, and saponin, wine acid, malic acid, and tartaric acid It contains organic acids, such as vitamin A and also contains a large amount of sugar. The seeds contain palmitic acid, oleic acid, linoleic acid, and the like. Among the components, cornin is known to have an excitatory action of the parasympathetic nerve. Traditionally, herbal medicine has been used in herbal medicine. According to "Donguibogam", "Hyangyakgyeolseongbang", etc., it is said to have efficacy such as Gangeum, Shinjeong and Singi, and convergence. It is used as a medicine for headaches, tinnitus, sea sickness, fever, and excessive menstruation, and is also used in folk remedies such as cold sweat and enuresis. It is also dressed as tea or alcohol, and has effects such as Jeehan (止汗) and Boeum (補陰).
오미자(Schisandra chinensis)는 공 모양으로 지름 약 1cm이고 짙은 붉은 빛깔이다. 속에는 붉은 즙과 불그스레한 갈색 종자가 1∼2개 들어 있다. 단맛, 신맛, 쓴맛, 짠맛, 매운맛의 5가지 맛이 나며 그 중에서도 신맛이 강하다. 종류에는 오미자(북오미자), 남오미자, 흑오미자 등이 있다. 시잔드린, 고미신, 시트럴, 사과산, 시트르산 등의 성분이 들어 있어 심장을 강하게 하고 혈압을 내리며 면역력을 높여 주어 강장제로 쓴다. 폐 기능을 강하게 하고 진해, 거담 작용이 있어서 기침이나 갈증 등을 치료하는 데 도움이 된다. 말린 열매를 찬물에 담가 붉게 우러난 물에 꿀, 설탕을 넣어 음료로 마시거나 화채나 녹말편을 만들어 먹는다. 밤, 대추, 미삼을 함께 넣고 끓여 차를 만들거나 술을 담그기도 한다.Omija (Schisandra chinensis) is a ball, about 1 cm in diameter, and is dark red in color. The inside contains 1 to 2 red juice and reddish brown seeds. It has 5 flavors of sweet, sour, bitter, salty, and spicy, and strong acidity among them. Types include Omija (Northern Omija), South Omija, and Black Omija. Contains ingredients such as cyzandrine, gomisin, citral, malic acid, and citric acid, which strengthens the heart, lowers blood pressure, and boosts immunity, making it a tonic. It strengthens the lung function and has antitussive and expectorant properties, which helps to treat cough or thirst. Soak the dried fruit in cold water, add honey and sugar to the red water, drink it as a drink, or make a flower or starch piece to eat. Chestnuts, jujube, and white ginseng are mixed together to make tea or to drink alcohol.
백하수오(Cynanchum wilfordii)는 자양(字樣), 강장(强壯), 보혈(補血), 익정(益情)의 용도로 사용되며, 레시틴성분과 부신피질호르몬 형태의 물질이 함유되어 있다. 콜레스테롤을 감소시켜 동맥경화증을 예방하고 연동운동을 촉진시켜 통변시키며, 신경쇠약을 안정시키고 조루증을 치료한다. 동의보감에는 염증을 삭히고 가래와 담을 없애며 종기, 치질, 만성피로로 몸이 마르는 것, 산후병, 대하 등을 치료한다.Baekhasuo (Cynanchum wilfordii) is used for nourishment, tonicity, blood, and Ikjeong, and contains lecithin and adrenal cortical hormone substances. It reduces cholesterol, prevents arteriosclerosis, promotes peristalsis, makes bowel movements, stabilizes nervous breakdown, and treats premature ejaculation. Donguibogam cuts inflammation, removes phlegm and phlegm, and treats boils, hemorrhoids, dryness with chronic fatigue, postpartum disease, and treatment.
본 발명과 관련된 선행기술로는 대한민국 공개특허 10-2017-0003395호에 고추 추출물을 유효성분으로 함유하는 혈관성 치매 또는 알츠하이머의 예방 및 치료용 약학적 조성물에 공지되어 있고 대한민국 공개특허 10-2012-0099960호에 식물에서 유래한 플라보놀을 유효성분으로 하는 치매 예방 및 치료용 조성물에 관한 것이 공지되어있다. 그러나 현재까지 생지황 뿌리, 홍삼근, 백복령 뿌리, 구기자 열매, 산수유 열매, 오미자 열매 및 백하수오 뿌리 등 7종의 허브식물과 백밀의 열수추출물을 이용하여 면역증강 또는 치매 예방 및 개선용 식품 조성물에 대하여는 공지된 바 없다.Prior art related to the present invention is known from the Republic of Korea Patent Publication No. 10-2017-0003395 in a pharmaceutical composition for the prevention and treatment of vascular dementia or Alzheimer's containing pepper extract as an active ingredient, and Republic of Korea Patent Publication 10-2012-0099960 It is known that a composition for preventing and treating dementia using flavonol derived from Hoe plant as an active ingredient. However, until now, it is known about food compositions for preventing or improving immunity or dementia by using 7 kinds of herbal plants and hot water extracts of white wheat, such as raw red bean root, red ginseng root, Baekbokryeong root, goji berry fruit, cornus fruit, Omija fruit, and white sorghum root. It has never been done.
따라서, 본 발명의 목적은 생지황 뿌리, 홍삼근, 백복령 뿌리, 구기자 열매, 산수유 열매, 오미자 열매 및 백하수오 뿌리 등 7종의 허브식물과 백밀의 열수추출물을 이용하여 면역증강 또는 치매 예방 및 개선용 식품 조성물을 제공하는 데 있다.Therefore, the object of the present invention is a food used for preventing or improving immunity or dementia by using 7 kinds of herbal plants and hot water extracts of white wheat, such as raw red bean root, red ginseng root, Baekbokryeong root, goji berry fruit, cornus fruit, Omija fruit, and white sorghum root. In providing a composition.
본 발명의 상기 목적은 식품 조성물 총 중량에 대하여 생지황 뿌리 20중량%, 홍삼근 20중량%, 백복령 뿌리 10중량%, 백밀(꿀) 10중량%, 구기자 열매 10중량%, 산수유 열매 10중량%, 오미자 열매 10중량% 및 백하수오 뿌리 10중량%를 수세건조 후 세밀한 것을 배합한 혼합물에 상기 혼합물 총 중량의 20배(w/w)의 정제수를 가수하여 약탕기로 3시간 동안 열수추출하는 단계와; 상기 단계에서 얻은 허브식물의 열수추출물을 2겹 거즈로 여과한 다음 회전식 증발기로 감압농축하는 단계와; 상기 단계에서 얻은 감압농축한 열수추출물을 동물실험 및 세포실험을 통해 효능을 시험하는 단계로 이루어지고 상기에서 얻은 열수추출물을 공시재료로 사용하여 면역증강과 치매 예방 및 개선 실험을 수행하고 그 결과를 평가함으로써 달성하였다.The above object of the present invention is 20% by weight raw root root, 20% by weight of red ginseng root, 10% by weight of Baekbokryeong root, 10% by weight of white wheat (honey), 10% by weight of goji berry fruit, 10% by weight of cornflower fruit, Omija 10% by weight of the fruit and 10% by weight of white sorghum roots, followed by washing with water and adding purified water of 20 times (w / w) of the total weight of the mixture to a mixture of fine mixtures, followed by extracting hot water with a water heater for 3 hours; Filtering the hot water extract of the herb plant obtained in the above step with two layers of gauze and then concentrating under reduced pressure with a rotary evaporator; It consists of the step of testing the efficacy of the decompressed concentrated hot water extract obtained in the above step through animal experiments and cell experiments, and using the obtained hot water extract as a public disclosure material to perform immune enhancement and dementia prevention and improvement experiments, and the results. It was achieved by evaluation.
본 발명은 생지황 뿌리, 홍삼근, 백복령 뿌리, 구기자 열매, 산수유 열매, 오미자 열매 및 백하수오 뿌리 등 7종의 허브식물과 백밀을 중량비 2:2:1:1:1:1:1:1의 열수추출물을 제공하는 효과가 있고 면역증강 또는 치매 예방 및 개선용 식품 조성물을 제공하는 뛰어난 효과가 있다.In the present invention, 7 kinds of herb plants and white wheat, such as raw huanghuang root, red ginseng root, baekboknyeong root, goji berry fruit, cornus fruit, omija fruit, and white sorghum root, have a weight ratio of 2: 2: 1: 1: 1: 1: 1: 1. It has an effect of providing an extract and has an excellent effect of providing a food composition for preventing or improving immunity or dementia.
도 1은 본 발명에 따른 생지황 뿌리, 홍삼근, 백복령 뿌리, 구기자 열매, 산수유 열매, 오미자 열매 및 백하수오 뿌리 등 8종 약재의 열수추출물을 실험동물에 복강투여에 따른 체중 변화를 나타낸 그래프이다.
도 2는 본 발명에 따른 생지황 뿌리, 홍삼근, 백복령 뿌리, 백밀(꿀), 구기자 열매, 산수유 열매, 오미자 열매 및 백하수오 뿌리 등 8종 약재의 열수추출물의 DPPH 라디칼 소거능을 나타낸 그래프이다.
도 3은 본 발명에 따른 생지황 뿌리, 홍삼근, 백복령 뿌리, 백밀(꿀), 구기자 열매, 산수유 열매, 오미자 열매 및 백하수오 뿌리 등 8종 약재의 열수추출물을 RAW 264.7 세포에 투여했을 때 NO 방출량을 나타낸 그래프이다.
도 4는 본 발명에 따른 생지황 뿌리, 홍삼근, 백복령 뿌리, 백밀(꿀), 구기자 열매, 산수유 열매, 오미자 열매 및 백하수오 뿌리 등 8종 약재의 열수추출물을 C57BL/6 마우스 비장세포에 투여했을 때 B-림프구 활성을 나타낸 그래프이다.
도 5는 본 발명에 따른 생지황 뿌리, 홍삼근, 백복령 뿌리, 백밀(꿀), 구기자 열매, 산수유 열매, 오미자 열매 및 백하수오 뿌리 등 8종 약재의 열수추출물을 5xFAD 마우스에 복강투여했을 때 마크로파지 활성을 나타낸 그래프이다.
도 6은 본 발명에 따른 생지황 뿌리, 홍삼근, 백복령 뿌리, 백밀(꿀), 구기자 열매, 산수유 열매, 오미자 열매 및 백하수오 뿌리 등 8종 약재의 열수추출물을 5xFAD 마우스에 복강투여했을 때 SIRT1 발현량을 나타낸 그래프이다.
도 7은 본 발명에 따른 생지황 뿌리, 홍삼근, 백복령 뿌리, 백밀(꿀), 구기자 열매, 산수유 열매, 오미자 열매 및 백하수오 뿌리 등 8종 약재의 열수추출물을 5xFAD 마우스에 복강투여했을 때 Amyloid beta의 발현량을 나타낸 그래프이다.
도 8은 본 발명에 따른 생지황 뿌리, 홍삼근, 백복령 뿌리, 백밀(꿀), 구기자 열매, 산수유 열매, 오미자 열매 및 백하수오 뿌리 등 8종 약재의 열수추출물을 HEK293 세포에 투여했을 때 sAPPα의 발현량을 나타낸 그래프이다.
도 9는 본 발명에 따른 생지황 뿌리, 홍삼근, 백복령 뿌리, 백밀(꿀), 구기자 열매, 산수유 열매, 오미자 열매 및 백하수오 뿌리 등 8종 약재의 열수추출물을 HEK293 세포에 투여했을 때 sAPPβ의 발현량을 나타낸 그래프이다.Figure 1 is a graph showing the weight change according to the intraperitoneal administration of 8 kinds of hot water extracts, such as raw huanghuang root, red ginseng root, Baekbokryeong root, goji berry fruit, cornus berry, Omija fruit and Baekshou root, according to the present invention.
Figure 2 is a graph showing the DPPH radical scavenging ability of hot water extracts of 8 kinds of herbs, such as saengjihwang root, red ginseng root, Baekbokryeong root, Baekmil (honey), goji berry, cornus fruit, Omija fruit and Baekshao root according to the present invention.
FIG. 3 shows the NO emission amount when the hot water extracts of 8 kinds of medicines, such as raw red bean root, red ginseng root, Baekbokryeong root, white wheat (honey), goji berry, cornus fruit, Omija fruit, and Baeksuo root, according to the present invention are administered to RAW 264.7 cells. It is the graph shown.
Figure 4 is when the administration of hot water extracts of 8 kinds of herbs, such as raw red beans root, red ginseng root, Baekbokryeong root, white wheat (honey), goji berry, cornus fruit, Omija fruit, and white sorghum root according to the present invention to C57BL / 6 mouse spleen cells It is a graph showing B-lymphocyte activity.
FIG. 5 shows macrophage activity when 5xFAD mice were intraperitoneally administered hot water extracts of 8 kinds of herbs, such as saengjihwang root, red ginseng root, Baekbokryeong root, white wheat (honey), goji berries, cornus fruit, Omija fruit, and Baekssuo root according to the present invention. It is the graph shown.
FIG. 6 shows SIRT1 expression level when intraperitoneally administered 5xFAD mice with 8 kinds of hot water extracts, such as saengjihwang root, red ginseng root, Baekbokryeong root, white wheat (honey), goji berry, cornus fruit, Omija fruit, and Baeksuo root, according to the present invention. It is a graph showing.
FIG. 7 shows the Amyloid beta of 8 kinds of hot water extracts, such as saengjihwang root, red ginseng root, Baekbokryeong root, white wheat (honey), goji berry, cornus fruit, Omija fruit, and white sorghum root according to the present invention, intraperitoneally administered to a 5xFAD mouse. It is a graph showing the expression level.
Figure 8 is the amount of expression of sAPPα when administered to HEK293 cells with hot water extracts of 8 medicinal materials, such as saengjihwang root, red ginseng root, Baekbokryeong root, white wheat (honey), goji berry, cornus fruit, Omija fruit and Baekshao root according to the present invention It is a graph showing.
FIG. 9 shows the expression level of sAPPβ when 8 kinds of hot water extracts, such as saengjihwang root, red ginseng root, Baekbokryeong root, white wheat (honey), goji berry, cornus fruit, Omija fruit and Baekshao root, according to the present invention are administered to HEK293 cells. It is a graph showing.
본 발명은 치매 예방 및 개선용 식품 조성물을 제공한다.The present invention provides a food composition for preventing and improving dementia.
본 발명에 따르면 상기 식품 조성물은 생지황 뿌리, 홍삼근, 백복령 뿌리, 백밀(꿀), 구기자 열매, 산수유 열매, 오미자 열매 및 백하수오 뿌리로 이루어진 혼합 허브식물에서 열수추출한다.According to the present invention, the food composition extracts hot water from a mixed herb plant consisting of raw red beans root, red ginseng root, Baekbokryeong root, white wheat (honey), goji berry, cornus berry, Omija fruit, and white sorghum root.
본 발명은 하기의 구체적인 실시예 및 실험예에 의해 보다 구체적으로 설명되나, 하기 실시예 및 실험예는 본 발명을 예시하기 위한 것으로 본 발명의 권리범위가 이에 한정하는 것으로 의도되지는 않는다.The present invention is explained in more detail by the following specific examples and experimental examples, but the following examples and experimental examples are intended to illustrate the present invention and are not intended to limit the scope of the present invention.
실시예1. 본 발명 8종 약재의 허브식물의 열수추출물의 제조Example 1. Preparation of the hot water extract of the herb plant of 8 kinds of the present invention
생지황 뿌리 200g, 홍삼근 200g, 백복령 뿌리 100g, 백밀(꿀) 100g, 구기자 열매 100g, 산수유 열매 100g, 오미자 열매 100g 및 백하수오 뿌리 100g을 칭량하여 세밀하고 배합한 다음(표1) 증류수를 허브식물 총 중량의 20배(w/w)를 가수한 후 가스 약탕기로 3시간 동안 열수추출하였다. 상기 열수추출물을 냉각한 후 2겹 거즈로 여과한 다음 회전식 증발기로 감압농축하여 열수추출물의 농축액 2kg을 수득하였다.Weighing 200 g of raw huanghuang root, 200 g of red ginseng root, 100 g of Baekbokryeong root, 100 g of white wheat (honey), 100 g of goji berry, 100 g of sorghum fruit, 100 g of Omija fruit, and 100 g of white sorghum root are weighed and mixed (Table 1), and then distilled water is used as a total of herbal plants. After adding 20 times the weight (w / w), the hot water was extracted for 3 hours using a gas water heater. After cooling the hot water extract, filtered with two-ply gauze, and concentrated under reduced pressure with a rotary evaporator to obtain 2 kg of concentrate of the hot water extract.
실시예2. 실험동물 준비실험동물은 7주령의 수컷 5xFAD 마우스와 C57BL/6를 구입하여 1주일간 새로운 사육환경(온도 22±3℃, 습도 50±10%)에 적응시키고 물과 사료는 자유롭게 섭식하도록 하였다. Example 2. Preparation of Experimental Animals Experimental animals purchased 7-week-old male 5xFAD mice and C57BL / 6, adapted to a new breeding environment (
실험예1. 본 발명 8종 약재의 열수추출물 투여시 체중변화Experimental Example 1. Weight change when administering the hot water extract of 8 kinds of the present invention
상기 실시예1에 따라 제조된 본 발명 8종 약재의 열수추출물의 독성을 확인하기 위해 상기 실시예2의 실험동물에 1, 10, 100mg/mL 농도로 복강투여하였고 1주일간 실험동물의 체중을 측정하여 변화를 확인하였다. 대조군은 생리식염수를 복강투여하였다.To confirm the toxicity of the hot water extract of the eight kinds of the present invention prepared according to Example 1, the experimental animals of Example 2 were administered intraperitoneally at a concentration of 1, 10, 100 mg / mL and the body weight of the experimental animals was measured for one week. To confirm the change. The control group was administered with physiological saline intraperitoneally.
실험 결과, 도1에서 알 수 있듯이 본 발명 8종 약재의 열수추출물 1~100mg/mL 농도에서 실험동물의 급격한 체중변화가 나타나지 않아 8종 약재의 열수추출물 투여가 건강에 유해성이 없음을 확인하였다.As shown in FIG. 1, it was confirmed that the administration of the hot water extract of the 8 kinds of medicines was not harmful to health because the rapid weight change of the experimental animals did not appear at the concentration of 1 to 100 mg / mL of the hot water extract of the 8 kinds of medicines of the present invention.
실험예2. 본 발명 8종 약재의 열수추출물의 독성Experimental Example 2. Toxicity of hot water extract of 8 kinds of medicine of the present invention
본 발명 상기 실시예1에서 얻은 8종 약재의 열수추출물의 독성을 측정하였다. 이를 위해 RAW 264.7 세포가 5 x 104cells/well이 되도록 24 well plate에 분주하고 24시간 배양하였다. 배양한 세포에 본 발명 8종 약재의 열수추출물을 1, 10 및 100mg/mL 농도로 함유한 세포배양액으로 교환하여 세포를 배양하였다. 세포를 48시간 배양한 후 MTT assay를 실시하여 살아있는 세포수를 formazan을 isopropanol에 용해시킨 다음 570nm의 파장에서 흡광도를 측정하였다.대조군으로는 생리식염수를 사용하였다.The present invention was measured the toxicity of the hot water extract of the eight kinds of medicine obtained in Example 1 above. To this end, RAW 264.7 cells were dispensed into 24 well plates so as to be 5 x 10 4 cells / well and cultured for 24 hours. The cells were cultured by exchanging the cultured cells with a cell culture solution containing hot water extracts of the 8 kinds of the present invention at concentrations of 1, 10 and 100 mg / mL. After culturing the cells for 48 hours, the MTT assay was performed to dissolve live cell numbers in formazan in isopropanol, and absorbance was measured at a wavelength of 570 nm. As a control group, physiological saline was used.
실험 결과, 하기 표2에서 알 수 있듯이 본 발명 8종 약재의 열수추출물은 독성이 없는 무독성(non-toxic)임을 확인하였다As a result of the experiment, as shown in Table 2 below, it was confirmed that the hot water extract of the eight kinds of medicines of the present invention is non-toxic and non-toxic.
실험예3. 항산화활성 측정상기 실시예1에서 수득한 본 발명 생지황 뿌리, 홍삼근, 백복령 뿌리, 백밀(꿀), 구기자 열매, 산수유 열매, 오미자 열매 및 백하수오 뿌리 등 8종 약재의 열수추출물의 항산화능을 측정하기 위해 DPPH(1,1-diphenyl-2-picrylhydrazyl) radical scavenging activity를 측정하였다. 이를 위해 200uM DPPH 1mL와 상기 실시예1에서 수득한 본 발명 8종 약재의 열수추출물 1mL를 혼합하여 상온, 암소에서 30분 동안 반응시킨 후 517nm에서 흡광도를 측정하였다. 양성대조군으로는 ascrobic acid를 사용하였고 음성대조군은 LPS로 자극을 주었다. DPPH radical 소거능(%)은 하기 수학식1의 방법으로 계산하였다.실험 결과, 도2에서 알 수 있듯이 음성 대조군에 비해 본 발명 8종 약재의 열수추출물의 DPPH radical 소거능이 증가되어 항산화 기능성 물질이 함유되었음을 확인하였다.Experimental Example 3. Measurement of Antioxidant Activity Measuring the antioxidant capacity of hot water extracts of 8 kinds of medicines, such as the present invention obtained from Example 1, roots, red ginseng roots, Baekbokryeong roots, white wheat (honey), goji berry, cornus fruit, Omija fruit, and white sorghum root In order to measure DPPH (1,1-diphenyl-2-picrylhydrazyl) radical scavenging activity. To this end, 1 mL of 200 uM DPPH and 1 mL of the hot water extract of the eight pharmaceuticals of the present invention obtained in Example 1 were mixed and reacted at room temperature for 30 minutes in a cow, and absorbance was measured at 517 nm. Ascrobic acid was used as the positive control and negative control was stimulated with LPS. DPPH radical scavenging capacity (%) was calculated by the method of
실험예4. NO 방출량을 통한 면역활성 측정Experimental Example 4. Immune activity measurement through NO emission
상기 실시예1에서 수득한 본 발명 생지황 뿌리, 홍삼근, 백복령 뿌리, 백밀(꿀), 구기자 열매, 산수유 열매, 오미자 열매 및 백하수오 뿌리 등 8종 약재의 열수추출물을 이용하여 NO 방출량을 측정하여 면역활성을 확인하였다. 이를 위해 RAW 264.7 세포를 LPS 100ng/mL 농도로 자극을 준 후 본 발명 8종 약재의 열수추출물을 10mg/mL 농도로 처리하여 NO 방출량을 측정하였다. 대조군으로는 LPS 무처리군을 이용하였다.Immunity by measuring NO emission using hot water extracts of 8 kinds of medicines, such as raw gin yellow root, red ginseng root, Baekbokryeong root, white wheat (honey), goji berry, cornus fruit, Omija fruit, and white sorghum root obtained in Example 1 Activity was confirmed. To this end, RAW 264.7 cells were stimulated at a concentration of 100 ng / mL LPS, and then treated with a hot water extract of 8 kinds of the present invention at a concentration of 10 mg / mL to measure the NO release amount. As a control, an LPS-free group was used.
실험 결과, 도3에서 알 수 있듯이 10mg/mL 농도에서 8종 약재의 열수추출물의 NO 방출량이 74.3%로 다량의 NO를 방출시켜 면역 활성이 현저히 증진됨을 확인하였다.As shown in FIG. 3, it was confirmed that the immune activity was significantly enhanced by releasing a large amount of NO to 74.3% of the hot water extract of 8 medicinal substances at a concentration of 10 mg / mL.
실험예5. B-림프구 자극활성 측정Experimental Example 5. B-lymphocyte stimulation activity measurement
상기 실시예1에서 수득한 본 발명 생지황 뿌리, 홍삼근, 백복령 뿌리, 백밀(꿀), 구기자 열매, 산수유 열매, 오미자 열매 및 백하수오 뿌리 등 8종 약재의 열수추출물에 대한 B-림프구 자극활성을 확인하기 위해 상기 실시예2에 기재된 C57BL/6 마우스를 비장적출실험에 사용하였다. 비장세포는 10% FBS가 첨가된 RPMI1640 배지에서 배양하여 48well plate에 옮긴 후 LPS를 25ug/mL 농도로 자극을 준 후 상기 실시예1에서 얻은 본 발명 8종 약재의 열수추출물을 10mg/mL 농도로 처리하여 2일동안 배양하였다. 대조군은 생리식염수를 처리하여 배양하였다.The stimulation activity of B-lymphocytes against the hot water extracts of 8 kinds of medicines, such as the present invention obtained in Example 1, root root, red ginseng root, Baekbokryeong root, white wheat (honey), goji berry fruit, cornus fruit, Omija fruit, and white sewage root To do this, the C57BL / 6 mice described in Example 2 were used for spleen extraction experiments. Splenocytes were cultured in RPMI1640 medium with 10% FBS added, transferred to a 48well plate, stimulated with LPS at a concentration of 25 ug / mL, and then hot water extract of the 8 kinds of medicines of the present invention obtained in Example 1 at a concentration of 10 mg / mL. Treated and cultured for 2 days. The control group was cultured by treatment with physiological saline.
실험결과, 도4에서 알 수 있듯이 대조군에 비해 본 발명 8종 약재의 열수추출물에서 B-림프구가 활성화되어 면역활성이 현저히 증강되는 것을 확인하였다.As shown in Fig. 4, it was confirmed that the B-lymphocyte is activated in the hot water extract of the eight kinds of the present invention compared to the control group, thereby significantly enhancing the immune activity.
실험예6. 마크로파지 활성을 통한 면역활성 측정Experimental Example 6. Measurement of immune activity through macrophage activity
상기 실시예1에서 수득한 본 발명 생지황 뿌리, 홍삼근, 백복령 뿌리, 백밀(꿀), 구기자 열매, 산수유 열매, 오미자 열매 및 백하수오 뿌리 등 8종 약재의 열수추출물을 100mg/kg 농도로 상기 실시예2의 5xFAD 마우스에 복강투여하고 대조군에는 생리식염수를 동일조건으로 투여하였다. 마우스에 복강 투여 2일 후 희생시켜 마크로파지(macrophage)를 수득하였다. 수득한 마크로파지를 1x108 개/mL 농도로 RPMI 1640 배지에 재분산시키고 분산액을 200uL씩 분주한 다음 37℃에서 24시간 동안 5% CO2 배양기에서 배양시켰고 0.1% Triton X-100을 첨가하여 세포막을 용해시켜 분비되는 리소좀의 포스파타아제의 양을 ELISA reader기로 405nm에서 흡광도를 측정하여 마크로파지 활성 증강을 통해 면역활성을 측정하였다. The present invention obtained in Example 1, the raw medicinal root, red ginseng root, Baekbokryeong root, white wheat (honey), goji berry fruit, cornus fruit, Omija fruit, and white sorghum root, etc., the hot water extract of 8 kinds of medicine at the concentration of 100mg / kg Intraperitoneally administered to 5xFAD mice of 2, the control group was administered with physiological saline under the same conditions. The mice were sacrificed 2 days after intraperitoneal administration to obtain macrophage. The obtained macrophages were redispersed in RPMI 1640 medium at a concentration of 1x10 8 pcs / mL, the dispersion was dispensed 200uL, and then cultured in a 5% CO 2 incubator at 37 ° C for 24 hours, and 0.1% Triton X-100 was added to the cell membrane. The amount of phosphatase of the lysosomal secreted by lysis was measured by absorbance at 405 nm with an ELISA reader, and immunological activity was measured by enhancing macrophage activity.
실험 결과, 도5에서 알 수 있듯이 양성 대조군에 비해 본 발명 8종 약재의 열수추출물을 투여한 실험군에서 마크로파지의 활성이 증가하는 것이 확인되어 면역활성 증강효과가 입증되었다.As shown in FIG. 5, it was confirmed that the activity of the macrophage was increased in the experimental group to which the hot water extract of the eight kinds of the present invention was administered compared to the positive control group, and the immune activity enhancing effect was proved.
실험예7. SIRT1 수준 증가 측정Experimental Example 7. SIRT1 level increase measurement
치매 예방 및 개선 효과를 확인하기 위해 상기 실시예1에서 수득한 본 발명 생지황 뿌리, 홍삼근, 백복령 뿌리, 백밀(꿀), 구기자 열매, 산수유 열매, 오미자 열매 및 백하수오 뿌리 등 8종 약재의 추출물을 100mg/kg 농도로 상기 실시예2의 5xFAD 마우스에 복강투여하여 SIRT1 유전자의 발현량을 확인하였다. 마우스에 복강 투여 2일 후 희생시켜 뇌조직을 적출하여 액화질소로 급속 냉각시켰고 실험시 사용하였다. 상기단계에서 적출한 뇌조직을 BCA 정량법으로 단백질량을 정량하였고 50ug의 단백질을 10% SDS-PAGE 젤을 이용하여 웨스턴블롯을 시행하여 SIRT1의 발현량을 확인하였다. 음성 대조군으로는 생리식염수를 양성 대조군으로는 resveratrol 10uM 농도로 투여하였다.In order to confirm the effect of preventing and improving dementia, the extracts of 8 kinds of medicines, such as the present invention obtained in Example 1, roots of the present invention, red ginseng root, Baekbokryeong root, white wheat (honey), goji berry, cornus fruit, Omija fruit, and white sorghum root The expression level of the SIRT1 gene was confirmed by intraperitoneal administration to the 5xFAD mouse of Example 2 at a concentration of 100 mg / kg. After 2 days of intraperitoneal administration to the mouse, brain tissue was sacrificed and rapidly cooled with liquid nitrogen and used in the experiment. The brain tissue extracted in the above step was quantified by BCA quantification, and 50 ug of protein was subjected to Western blot using 10% SDS-PAGE gel to confirm the expression level of SIRT1. As a negative control, physiological saline was administered at a concentration of 10 uM resveratrol as a positive control.
실험 결과, 도6에서 알 수 있듯이 본 발명 8종 약재의 열수추출물이 양성 대조군에 비해 SIRT1 발현량을 증가시키는 것을 확인하였다. 이로써 본 발명 8종 약재의 열수추출물의 치매 예방 및 개선효과를 확인하였다.As shown in FIG. 6, it was confirmed that the hot water extract of the eight kinds of medicinal products of the present invention increased the amount of SIRT1 expression compared to the positive control. As a result, it was confirmed that the dehydration prevention and improvement effect of the hot water extract of the eight kinds of the present invention.
실험예8. Aβ 억제효과 측정Experimental Example 8. Aβ inhibitory effect measurement
치매의 원인이 되는 Aβ의 생성억제 효과를 측정하여 치매 예방 및 개선효과를 확인하기 위해 상기 실시예1에서 수득한 본 발명 생지황 뿌리, 홍삼근, 백복령 뿌리, 백밀(꿀), 구기자 열매, 산수유 열매, 오미자 열매 및 백하수오 뿌리 등 8종 약재의 열수추출물을 100mg/kg 농도로 상기 실시예2의 5xFAD 마우스에 복강투여하고 대조군에는 생리식염수를 동일조건으로 투여하였다. 마우스에 복강 투여 2일 후 희생시켜 혈액을 수득하였다. 수득한 혈액 중 상층액(serum)만을 분리해 Aβ 정량 Elisa kit(Thermo fisher)를 사용하여 Aβ량을 정량하였다.The present invention obtained in Example 1 to determine the effect of preventing and improving dementia by measuring the inhibitory effect of Aβ that causes dementia, red ginseng root, Baekboknyeong root, white wheat (honey), goji berries, cornus fruit, Eight medicinal hot water extracts, such as Omija fruit and white sorghum root, were intraperitoneally administered to the 5xFAD mouse of Example 2 at a concentration of 100 mg / kg, and physiological saline was administered to the control group under the same conditions. Mice were sacrificed 2 days after intraperitoneal administration to obtain blood. Only the supernatant (serum) in the obtained blood was separated and Aβ amount was quantified using the Elisa kit (Thermo fisher).
실험 결과, 도7에서 알 수 있듯이 생리식염수를 투여한 대조군에 비해 본 발명 8종의 허브식물의 열수추출물을 투여한 실험군에서 Aβ의 생성이 억제되는 것을 확인하였다. 이로써 본 발명 8종의 허브식물의 열수추출물에 의해 치매의 원인이 되는 Aβ의 생성이 현저히 억제하는 것을 확인하였다.As shown in Fig. 7, it was confirmed that the production of Aβ was suppressed in the experimental group administered with the hot water extract of the eight kinds of herb plants of the present invention compared to the control group administered with physiological saline. As a result, it was confirmed that the production of Aβ, which is a cause of dementia, was significantly suppressed by the hot water extract of the eight plant plants of the present invention.
실험예9. sAPPα 및 sAPPβ 발현량 측정Experimental Example 9. Measurement of sAPPα and sAPPβ expression levels
sAPPα 및 sAPPβ의 발현량을 측정하여 치매 예방 및 개선효과를 확인하기 위해 HEK293 세포를 plate에 10% FBS 및 1% streptomycin이 첨가된 DMEM배지를 이용하여 세포가 80~90% 자라도록 37℃, 5% CO2 배양기에서 배양하였고 상기 단계에서 얻은 배양액에서 배지를 제거 후 세포를 0.9mL DMEM 배지로 회수한 후 상기 실시예1에서 수득한 본 발명 생지황 뿌리, 홍삼근, 백복령 뿌리, 백밀(꿀), 구기자 열매, 산수유 열매, 오미자 열매 및 백하수오 뿌리 등 8종 약재의 열수추출물을 10mg/mL 농도로 현탁한 것 0.1mL 첨가하여 24시간 배양하였다. 대조군은 8종 약재의 열수추출물 대신 DMEM 배지 0.1mL을 첨가하여 이용하였다. 상기 단계에서 배양한 배양물을 10% SDS-PAGE 젤을 이용하여 웨스턴블롯을 시행하여 sAPPα 및 sAPPβ의 발현량을 확인하였다. To determine the effect of preventing and improving dementia by measuring the expression levels of sAPPα and sAPPβ, 37 ° C, 5 so that the cells grow 80-90% using DMEM medium with 10% FBS and 1% streptomycin added to HEK293 cells on a plate % CO 2 Incubated in the incubator, the medium was removed from the culture medium obtained in the above step, and then the cells were recovered with 0.9 mL DMEM medium, and then the present invention obtained in Example 1, raw saenghwang root, red ginseng root, Baekbokryeong root, white wheat (honey), goji berries 8 mL of hot water extracts, such as fruit, cornus fruit, Omija fruit, and white sorghum root, were suspended at a concentration of 10 mg / mL, and 0.1 mL was added and cultured for 24 hours. The control group was used by adding 0.1 mL of DMEM medium instead of the hot water extract of 8 kinds of medicine. The cultures cultured in the above step were subjected to Western blot using 10% SDS-PAGE gel to confirm the expression levels of sAPPα and sAPPβ.
실험 결과, 도8 및 도9에서 알 수 있듯이 대조군에 비해 본 발명 8종 약재의 열수추출물을 첨가한 실험군에서 sAPPα의 발현량은 증가하였고 sAPPβ의 발현량은 억제되는 것을 확인하였다. 이로써 본 발명 8종 약재의 열수추출물에 의해 SIRT1 유전자의 발현이 증가하여 α-세크라타제 발현이 증가하였고 이로써 sAPPα 발현량은 증가, sAPPβ의 발현량은 감소하는 것이 확인되어 치매의 원인이 되는 Aβ의 생성을 현저히 억제하는 것이 입증되었다.As shown in FIG. 8 and FIG. 9, it was confirmed that the expression level of sAPPα was increased and the expression level of sAPPβ was suppressed in the experimental group to which the hot water extract of the eight kinds of medicines of the present invention was added as compared to the control group. As a result, the expression of the SIRT1 gene was increased by the hot water extract of the eight kinds of the present invention, resulting in increased expression of α-secretase, thereby increasing the expression level of sAPPα and decreasing the expression level of sAPPβ, Aβ causing dementia. It has been demonstrated to significantly inhibit the production of.
또, 본 발명에 따르면 본 발명 생지황 뿌리, 홍삼근, 백복령 뿌리, 백밀(꿀), 구기자 열매, 산수유 열매, 오미자 열매 및 백하수오 뿌리 등 8종 약재의 열수추출물을 유효성분으로 함유하는 식품 조성물에 포함할 수 있는 식용가능한 담체, 부형제 또는 희석제로 락토즈, 덱스트로즈, 슈크로즈, 솔비톨, 만니톨, 전분, 아카시아 고무, 인산칼슘, 알지네이트, 젤라틴, 규산칼슘, 미세결정성 셀룰로즈, 폴리비닐피롤리돈, 셀룰로즈, 폴리비닐피롤리돈, 물, 설탕시럽, 메틸셀룰로즈, 메틸 하이드록시 벤조에이트, 프로필 하이드록시 벤조에이트, 활석, 스테아르산 마그네슘 및 미네랄 오일이 바람직하였다.In addition, according to the present invention, the present invention included in the food composition containing the hot water extract of 8 kinds of medicines, such as root, red ginseng root, Baekbokryeong root, white wheat (honey), goji berry, cornus fruit, Omija fruit, and white sorghum root as an active ingredient As an edible carrier, excipient or diluent, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone , Cellulose, polyvinylpyrrolidone, water, sugar syrup, methylcellulose, methyl hydroxy benzoate, propyl hydroxy benzoate, talc, magnesium stearate and mineral oil were preferred.
또, 상기 성분들 외에도 상업적으로 이용가능한 윤활제, 습윤제, 감미제, 향미제, 유화제, 현탁제, 보존제 중에서 선택하여 그 어느 하나의 성분을 추가로 더 포함할 수 있었다.In addition, in addition to the above components, a commercially available lubricant, wetting agent, sweetening agent, flavoring agent, emulsifying agent, suspending agent, preservative may be selected to further include any one component.
이하에는 본 발명 방법에 따라 제조된 본 발명 생지황 뿌리, 홍삼근, 백복령 뿌리, 백밀(꿀), 구기자 열매, 산수유 열매, 오미자 열매 및 백하수오 뿌리 등 8종 약재의 열수추출물을 함유하는 건강식품 조성물 제제의 구체적인 조성을 설명한다.Hereinafter, a preparation of a health food composition containing 8 types of hot water extracts, such as raw huanghuang root, red ginseng root, baekbokryeong root, white wheat (honey), wolfberry fruit, cornus fruit, omija fruit and white sorghum root, prepared according to the present invention method The specific composition of the will be described.
제조예1. 건강 보조 식품의 제조Preparation Example 1. Preparation of dietary supplements
상기 실시예1에서 수득한 본 발명 생지황 뿌리, 홍삼근, 백복령 뿌리, 백밀(꿀), 구기자 열매, 산수유 열매, 오미자 열매 및 백하수오 뿌리 등 8종 약재의 열수추출물의 농축액을 함유하는 건강 보조 식품은 하기 표3의 성분함량으로 통상의 건강식품 제조방법에 따라 제조하였다. 본 제품은 환제, 캡슐제 등 제형으로 제품화 할 수 있다.The present invention obtained in Example 1, the health supplement food containing a concentrate of 8 kinds of hot water extracts, such as raw ginza root, red ginseng root, Baekbokryeong root, white wheat (honey), goji berry, cornus fruit, Omija fruit, and white sorghum root It was prepared according to the conventional method for producing healthy foods with the ingredients in Table 3. This product can be commercialized in formulations such as pills and capsules.
제조예2. 발효 음료 제조상기 실시예1에서 수득한 본 발명 생지황 뿌리, 홍삼근, 백복령 뿌리, 백밀(꿀), 구기자 열매, 산수유 열매, 오미자 열매 및 백하수오 뿌리 등 8종 약재의 열수추출물의 농축액이 함유된 음료를 하기 표4의 함량으로 통상의 음료 제조방법에 따라 제조하였다. 본 제품은 팩의 제형으로 제품화하였다.Preparation Example 2. Preparation of fermented beverage The beverage obtained from Example 1 of the present invention contains a concentrate of hot water extracts of 8 kinds of medicines, such as the roots of the present invention, red ginseng root, Baekbokryeong root, white wheat (honey), goji berry, cornus fruit, Omija fruit, and white sorghum root. It was prepared according to the conventional beverage production method in the content of Table 4 below. This product was formulated as a pack formulation.
이상 설명한 바와 같이 본 발명 생지황 뿌리, 홍삼근, 백복령 뿌리, 백밀(꿀), 구기자 열매, 산수유 열매, 오미자 열매 및 백하수오 뿌리 등 8종 약재의 열수추출물은 면역활성 증진은 물론 치매 예방 및 개선에 뛰어난 효과가 있으므로 건강 기능성 식품 산업상 매우 유용한 발명인 것이다.As described above, the hot water extracts of 8 kinds of medicines, such as the present invention raw root, red ginseng root, Baekbokryeong root, white wheat (honey), goji berry, cornus fruit, Omija fruit, and white sorghum root, are excellent in improving immunity and preventing and improving dementia. Because it is effective, it is a very useful invention in the health functional food industry.
Claims (3)
제조된 열수추출물 농축액을 담체, 부형제 또는 희석제로 락토즈, 덱스트로즈, 슈크로즈, 솔비톨, 만니톨, 전분, 아카시아 고무, 인산칼슘, 알지네이트, 젤라틴, 규산칼슘, 폴리비닐피롤리돈, 셀룰로즈, 물, 설탕시럽, 메틸셀룰로즈, 메틸 하이드록시 벤조에이트, 프로필 하이드록시 벤조에이트, 활석, 스테아르산 마그네슘 및 미네랄 오일 중에서 선택되는 어느 하나의 첨가제와 혼합하여 열수추출물을 유효성분으로 함유하는 식품 조성물을 제조하는 단계;를 포함하는 것을 특징으로 하는
아밀로이드-베타의 생성을 억제하는 치매 예방 및 개선용 식품 조성물의 제조방법.Raw Ginseng Root, Red Ginseng Root, Baekbokryeong Root, White Wheat, Goji Fruit, Cornus officinalis, Omija Fruit, and White Sewage Root in a powder obtained by fine-graining 8 kinds of herbs consisting of 2: 2: 1: 1: 1: 1: 1: 1 Preparing a hydrothermal extract concentrate by adding 20 times (w / w) purified water by adding water, extracting hot water for 3 hours, filtering with 2-ply gauze after cooling, and then concentrating under reduced pressure with a rotary evaporator; And
Prepared hot water extract concentrate as a carrier, excipient or diluent, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium silicate, polyvinylpyrrolidone, cellulose, water , Sugar syrup, methylcellulose, methyl hydroxy benzoate, propyl hydroxy benzoate, talc, magnesium stearate and any additive selected from mineral oils to be mixed with any additive selected to prepare a food composition containing a hot water extract as an active ingredient Characterized in that it comprises a;
Method for preparing food composition for preventing and improving dementia that suppresses the production of amyloid-beta.
상기 식품 조성물을 제조하는 단계는 젖산칼슘 및 젤라틴을 더 혼합하는 것을 특징으로 하는
아밀로이드-베타의 생성을 억제하는 치매 예방 및 개선용 식품 조성물의 제조방법.According to claim 1,
The step of preparing the food composition is characterized by further mixing calcium lactate and gelatin.
Method for preparing food composition for preventing and improving dementia that suppresses the production of amyloid-beta.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190108040A KR102092509B1 (en) | 2019-09-02 | 2019-09-02 | Food composition for preventing and improving of dementia |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190108040A KR102092509B1 (en) | 2019-09-02 | 2019-09-02 | Food composition for preventing and improving of dementia |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020180125455A Division KR20180117088A (en) | 2018-10-19 | 2018-10-19 | Food composition for preventing and improving of dementia |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20190104299A KR20190104299A (en) | 2019-09-09 |
KR102092509B1 true KR102092509B1 (en) | 2020-03-23 |
Family
ID=67951627
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020190108040A KR102092509B1 (en) | 2019-09-02 | 2019-09-02 | Food composition for preventing and improving of dementia |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102092509B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220159536A (en) | 2021-05-25 | 2022-12-05 | 제천한약영농조합법인 | Manufacturing method of Medical Herb Tea for Preventing and Alleviating Dementia |
KR20230099385A (en) | 2021-12-27 | 2023-07-04 | 참들애바이오푸드영농조합법인 | Composition for the prevention and treatment of dementia comprising the extract of polygoni multiflori radix |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101519852B1 (en) * | 2014-10-14 | 2015-05-14 | 부산대학교 산학협력단 | Composition comprising extract of Cynanchum wilfordii, Rehmannia glutinosa, Polygala tenuifolia and Acorus gramineus for memory or cognition disorder |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100592488B1 (en) * | 2004-01-15 | 2006-06-23 | 경희대학교 산학협력단 | Composition comprising the extract of crude drug complex having neuronal cell-protecting activity for preventing and treating the degenerative brain disease |
KR20090071704A (en) * | 2007-12-28 | 2009-07-02 | 퓨리메드 주식회사 | Composition for prevention and treatment of the dementia |
KR101564204B1 (en) * | 2015-06-12 | 2015-10-28 | 김병균 | the manufacture method of mixed liquor of schizandra berries extracts |
-
2019
- 2019-09-02 KR KR1020190108040A patent/KR102092509B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101519852B1 (en) * | 2014-10-14 | 2015-05-14 | 부산대학교 산학협력단 | Composition comprising extract of Cynanchum wilfordii, Rehmannia glutinosa, Polygala tenuifolia and Acorus gramineus for memory or cognition disorder |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220159536A (en) | 2021-05-25 | 2022-12-05 | 제천한약영농조합법인 | Manufacturing method of Medical Herb Tea for Preventing and Alleviating Dementia |
KR20230099385A (en) | 2021-12-27 | 2023-07-04 | 참들애바이오푸드영농조합법인 | Composition for the prevention and treatment of dementia comprising the extract of polygoni multiflori radix |
Also Published As
Publication number | Publication date |
---|---|
KR20190104299A (en) | 2019-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20190014376A (en) | Composition Comprising Sturgeon Extracts | |
KR102092509B1 (en) | Food composition for preventing and improving of dementia | |
KR100771524B1 (en) | Composition for improving liver function comprising herbal mixture extract | |
KR100771525B1 (en) | Composition for removing hangover comprising herbal mixture extract | |
KR101961356B1 (en) | Composition of Extract of Cirsium Japonicum and Manufacturing method thereof | |
JP4624263B2 (en) | A herbal preparation as a brain tonic, containing camellia and sesame | |
KR101910013B1 (en) | A composition for improving, preventing and treating of pain comprising herb extract | |
KR100638491B1 (en) | Compounds for relief of alcoholic hangover and drug containing the compounds | |
US7399491B2 (en) | Health promoting functional foods fortified with herbs | |
KR101880245B1 (en) | Food Composition for Anti-stress effect | |
KR100850503B1 (en) | Composition for improving erectile dysfunction and erection maintenance containing the extract of crude drug complex | |
KR20180058997A (en) | Pharmaceutical composition and food composition for preventing the growth of white hair or promoting the growth of black hair, and a process for preparing them | |
KR101248378B1 (en) | Pharmaceutical composition for arthritis treatment and prevention | |
Roy et al. | Herbs Used In Peptic Ulcer: A Review. | |
KR20130018432A (en) | Pharmaceutical composition comprising herbal extracts for preventing or treating importence, and functional food comprising this extracts | |
KR101167628B1 (en) | A composition comprising black ginseng for treating or preventing dementia and improving cognitive function | |
KR101618215B1 (en) | The pharmaceutical compositions for prevention or treatment of male infertility containing Rehmannia glutinosa Liboschitz var.purpurae Makino, Lycium chinense Miller, Aquillaria agallocha Roxburgh, Poria cocos Wolf, Panax ginseng C.A. Meyer and honey as a active ingredient | |
KR20180117088A (en) | Food composition for preventing and improving of dementia | |
WO2018182151A1 (en) | Functional food composition for prevention and alleviation of dementia | |
KR102588372B1 (en) | Composition comprising natural complex extract for prenenting, improving or treating gastritis and peptic ulcer | |
KR102330844B1 (en) | Composition For Improving Sexual Function Containing 17 Herbal Ingredients And Schisandra Chinensis, Rubus Coreanus, Lycium Chinense, Torilis Japonica, And Cuscuta Australis | |
KR102651713B1 (en) | Chocolate composition for relieving hangovers comprising Hovenia Dulcis fruit and Velvet Antlers, and the manufacturing method of chocolate for relieving hangovers using the same | |
KR102494072B1 (en) | Composition for improving or preventing depression comprising herbal extracts and method for preparing thereof | |
KR102406795B1 (en) | COMPOSITION COMPRISING EXTRACT OF POLYGONUM CUSPIDATUM SIEB. et ZUCC. AND CINNAMOMUM CASSIA BLUME FOR PREVENTING, IMPROVING OR TREATING OF COGNITIVE DYSFUCCTION | |
KR102158852B1 (en) | Pharmaceutical composition comprising the extract of lycium chinensis as an effective component for prevention or treatment of hypertension and health functional food comprising the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |